Nasal administration of a probiotic assemblage in allergic rhinitis: A randomised placebo-controlled crossover trial.
Lactobacillus
Lactococcus
Allergy
cytokines
mini-RQLQ
nasal allergen challenge
topical/nasal probiotics
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
03
01
2022
received:
10
11
2021
accepted:
14
01
2022
pubmed:
26
1
2022
medline:
3
6
2022
entrez:
25
1
2022
Statut:
ppublish
Résumé
Topical probiotics have been suggested as a treatment option for allergic rhinitis, as they may skew the immune response towards a beneficial type-1 non-allergic profile. So far observations in man have exclusively involved oral intake. The aim of this study was to examine whether a topical/nasal administration of a probiotic assemblage (PA) affects quality of life, symptoms and signs of allergic rhinitis in a nasal allergen challenge (NAC) model. In a placebo-controlled and crossover design, 24 patients with seasonal allergic rhinitis were randomised to topical/nasal administration with a PA of Lactobacillus rhamnosus SP1, Lactobacillus paracasei 101/37 and Lactococcus lactis L1A or placebo for 3 weeks. Participants and investigators were blind to treatment allocation. The last week of each treatment period was combined with a NAC series. Efficacy variables were "Mini-Rhinoconjunctivitis Quality of Life Questionnaire" (Mini-RQLQ), "Total Nasal Symptom Score" (TNSS), "Peak Nasal Inspiratory Flow" (PNIF) and "Fractional Exhaled Nitric Oxide" (FeNO). In addition, to assess whether or not the PA produced any pro-inflammatory effect per se, soluble analytes were monitored in nasal lavage fluids. Finally, bacterial cultures, sampled using swabs from the middle nasal meatus, were assessed for the presence of the PA by MALDI-TOF analysis. Administration of the PA did not produce any nasal symptoms (cf. placebo). An innate immune response was discerned within the PA run (cf. baseline), but no change in nasal lavage fluid levels of cytokines/mediators was observed cf. placebo except for IL-17/IL-17A (a minor increase in the PA run). Administration of the PA did neither affect Mini-RQLQ, TNSS, PNIF nor FeNO. No evidence of persistent colonization was observed. Topical/nasal administration of a PA comprising Lactobacillus rhamnosus SP1, Lactobacillus paracasei 101/37 and Lactococcus lactis L1A, while likely evoking a minor innate immune response yet being safe, does not affect quality of life, symptoms or signs of allergic rhinitis. not registered.
Sections du résumé
BACKGROUND
Topical probiotics have been suggested as a treatment option for allergic rhinitis, as they may skew the immune response towards a beneficial type-1 non-allergic profile. So far observations in man have exclusively involved oral intake. The aim of this study was to examine whether a topical/nasal administration of a probiotic assemblage (PA) affects quality of life, symptoms and signs of allergic rhinitis in a nasal allergen challenge (NAC) model.
METHODS
In a placebo-controlled and crossover design, 24 patients with seasonal allergic rhinitis were randomised to topical/nasal administration with a PA of Lactobacillus rhamnosus SP1, Lactobacillus paracasei 101/37 and Lactococcus lactis L1A or placebo for 3 weeks. Participants and investigators were blind to treatment allocation. The last week of each treatment period was combined with a NAC series. Efficacy variables were "Mini-Rhinoconjunctivitis Quality of Life Questionnaire" (Mini-RQLQ), "Total Nasal Symptom Score" (TNSS), "Peak Nasal Inspiratory Flow" (PNIF) and "Fractional Exhaled Nitric Oxide" (FeNO). In addition, to assess whether or not the PA produced any pro-inflammatory effect per se, soluble analytes were monitored in nasal lavage fluids. Finally, bacterial cultures, sampled using swabs from the middle nasal meatus, were assessed for the presence of the PA by MALDI-TOF analysis.
RESULTS
Administration of the PA did not produce any nasal symptoms (cf. placebo). An innate immune response was discerned within the PA run (cf. baseline), but no change in nasal lavage fluid levels of cytokines/mediators was observed cf. placebo except for IL-17/IL-17A (a minor increase in the PA run). Administration of the PA did neither affect Mini-RQLQ, TNSS, PNIF nor FeNO. No evidence of persistent colonization was observed.
CONCLUSIONS
Topical/nasal administration of a PA comprising Lactobacillus rhamnosus SP1, Lactobacillus paracasei 101/37 and Lactococcus lactis L1A, while likely evoking a minor innate immune response yet being safe, does not affect quality of life, symptoms or signs of allergic rhinitis.
TRIAL REGISTRATION
not registered.
Identifiants
pubmed: 35075723
doi: 10.1111/cea.14098
pmc: PMC9314659
doi:
Substances chimiques
Allergens
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
774-783Informations de copyright
© 2022 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
Références
Int J Inflam. 2012;2012:686739
pubmed: 22762009
Clin Exp Allergy. 2000 Jan;30(1):132-40
pubmed: 10606940
Nat Rev Microbiol. 2010 Mar;8(3):171-84
pubmed: 20157338
Allergy Asthma Clin Immunol. 2015 Apr 24;11(1):16
pubmed: 25945101
Microbiol Immunol. 2008 Aug;52(8):399-409
pubmed: 18667039
Laryngoscope Investig Otolaryngol. 2017 Nov 08;2(6):410-416
pubmed: 29299516
Allergy. 2002 Mar;57(3):243-6
pubmed: 11906339
Clin Exp Allergy. 2011 Apr;41(4):565-73
pubmed: 21395878
Allergy. 2019 Jan;74(1):100-110
pubmed: 29888398
Int Immunopharmacol. 2014 Mar;19(1):161-73
pubmed: 24394565
Respir Res. 2010 Feb 09;11:17
pubmed: 20144207
Inflamm Res. 2015 Nov;64(11):903-15
pubmed: 26342289
Arch Dis Child. 2009 Feb;94(2):92-8
pubmed: 18713796
J Appl Microbiol. 2013 Aug;115(2):319-33
pubmed: 23437848
Thorax. 2006 Sep;61(9):817-27
pubmed: 16936238
Clin Exp Allergy. 2007 Sep;37(9):1286-95
pubmed: 17845408
Clin Mol Allergy. 2016 Sep 28;14:12
pubmed: 27708552
Clin Transl Allergy. 2014 Jan 06;4(1):1
pubmed: 24393277
Clin Exp Allergy. 2022 Jun;52(6):774-783
pubmed: 35075723
J Nutr. 2010 Mar;140(3):713S-21S
pubmed: 20130079
BMJ. 1989 Nov 18;299(6710):1259-60
pubmed: 2513902
Clin Transl Allergy. 2015 Dec 09;5:41
pubmed: 26664720
Clin Exp Allergy. 2008 Aug;38(8):1282-9
pubmed: 18510694
Respir Med. 2014 Jun;108(6):830-41
pubmed: 24636813
Ann Allergy Asthma Immunol. 2007 Apr;98(4):316-21
pubmed: 17458426
Am J Rhinol Allergy. 2015 Jul-Aug;29(4):292-8
pubmed: 26163249
Tissue Barriers. 2014 May 12;2:e29166
pubmed: 25101232
Int Forum Allergy Rhinol. 2015 Jun;5(6):524-32
pubmed: 25899251
Ann Allergy Asthma Immunol. 2002 Aug;89(2):159-65
pubmed: 12197572
Pediatr Neonatol. 2014 Jun;55(3):181-8
pubmed: 24269033
Allergy. 2018 Oct;73(10):1954-1963
pubmed: 29869783
Nature. 2007 Oct 18;449(7164):819-26
pubmed: 17943118
EMBO Rep. 2011 Oct 28;12(11):1089-93
pubmed: 21979814
Int Forum Allergy Rhinol. 2016 Sep;6(9):956-63
pubmed: 27080343
Am J Rhinol Allergy. 2016 Sep 1;30(5):157-175
pubmed: 27442711